Pomalidomide Capsules 2 mg, 4 mg, 3 mg, and 4 mg Suppliers & Bulk Manufacturers

Available Forms: capsules.

Available Strengths: 2 mg, 4 mg, 3 mg, and 4 mg

Reference Brands: Talquetamide(US), Pomalyst(EU)

Category: Orphan Drugs

Pomalidomide is an immunomodulatory drug that enhances immune response and inhibits tumor growth by modulating cytokine production and stimulating T-cell activity. It effectively treats refractory multiple myeloma, improving survival, decreasing tumor burden, and supporting long-term disease control while supporting immune health.

Product Description: Pomalidomide capsules, marketed as Pomalyst, are approved in the US by the FDA and in the EU via EMA for relapsed and refractory multiple myeloma. Regulatory approval requires a comprehensive dossier including clinical efficacy, safety data, manufacturing standards, and pharmacovigilance plans. The FDA reviews clinical trial and quality data to ensure safety and effectiveness, while the EMA evaluates compliance with regional safety and manufacturing standards. For guidance on dossier preparation, regulatory pathways, and market access, visit PharmaTradz. Proper adherence to regional requirements supports timely approval, safe use, and widespread availability, helping improve long-term outcomes for multiple myeloma patients worldwide.